China Jinmao (00817) achieved a cumulative signed sales amount of 57.5 billion yuan in the first 6 months, a year-on-year increase of 7.78%.
China Jinmao (00817) announced that in June 2026, the company and its subsidiaries (the Group) achieved a signed sales amount of RMB 15.773 billion, an increase of 1.11% year-on-year, and a signed sales building area of 597,900 square meters.
China Jinmao (00817) announces that in June 2026, the company and its subsidiary companies (the Group) achieved a contracted sales amount of RMB 15.773 billion, an increase of 1.11% compared to the previous year, with a contracted sales area of 597,900 square meters.
As of June 30, 2026, during the six-month period, the Group has achieved a total contracted sales amount of RMB 57.5 billion, including the Changsha Meixihu International New Town project, the Nanjing Qinglongshan International Eco New Town project, the Ningbo Life Science City project, the Jiaxing Shanghai Window Smart Science City project, the Zhengzhou Erqi District Mazhai New Town project, the Wenzhou Aojiang International New Town project, the Jinhua Jinmao Future Science City project, and the Shanghai Hengmian Urban Operation project, representing an increase of 7.78% over the previous year, with a total contracted sales area of 2.2808 million square meters.
Additionally, as of June 30, 2026, the Group has obtained subscribed (but not yet contracted) property sales totaling RMB 0.791 billion.
Related Articles

On July 9th, ANTON OILFIELD (03337) spent approximately HK$2.9737 million to repurchase 3.63 million shares.

United Asia Pharmaceuticals' GEM IPO has passed review, and 12 products including sustained-release metoprolol succinate tablets have been approved by NMPA for listing and sales.

On July 9, Nayuki (02150) spent approximately HKD 825,700 to repurchase 1.2225 million shares.
On July 9th, ANTON OILFIELD (03337) spent approximately HK$2.9737 million to repurchase 3.63 million shares.

United Asia Pharmaceuticals' GEM IPO has passed review, and 12 products including sustained-release metoprolol succinate tablets have been approved by NMPA for listing and sales.

On July 9, Nayuki (02150) spent approximately HKD 825,700 to repurchase 1.2225 million shares.

RECOMMEND





